{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:04:37Z","timestamp":1789452277679,"version":"build-2803163510"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T00:00:00Z","timestamp":1307404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>CXCL10 is one of the key chemokines involved in trafficking of autoaggressive T cells to the islets of Langerhans during the autoimmune destruction of beta cells in type 1 diabetes (T1D). Blockade of CXCL10 or genetic deletion of its receptor CXCR3 results in a reduction of T1D in animal models. As an alternative to the use of neutralizing monoclonal antibodies to CXCL10 or CXCR3 we evaluated the small molecule CXCR3 antagonist NIBR2130 in a virus-induced mouse model for T1D. We found that the overall frequency of T1D was not reduced in mice administered with NIBR2130. An initial slight delay of diabetes onset was not stable over time, because the mice turned diabetic upon removal of the antagonist. Accordingly, no significant differences were found in the islet infiltration rate and the frequency and activity of islet antigen-specific T cells between protected mice administered with NIBR2130 and control mice. Our data indicate that in contrast to direct inhibition of CXCL10, blockade of CXCR3 with the small molecule antagonist NIBR2130 has no impact on trafficking and\/or activation of autoaggressive T cells and is not sufficient to prevent T1D.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2011.04426.x","type":"journal-article","created":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T11:57:28Z","timestamp":1307447848000},"page":"318-328","source":"Crossref","is-referenced-by-count":14,"title":["Small molecule CXCR3 antagonist NIBR2130 has only a limited impact on type 1 diabetes in a virus-induced mouse model"],"prefix":"10.1093","volume":"165","author":[{"given":"S","family":"Christen","sequence":"first","affiliation":[{"name":"Pharmazentrum Frankfurt\/ZAFES, Klinikum der Goethe Universit\u00e4t, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Holdener","sequence":"additional","affiliation":[{"name":"Pharmazentrum Frankfurt\/ZAFES, Klinikum der Goethe Universit\u00e4t, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Beerli","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Thoma","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bayer","sequence":"additional","affiliation":[{"name":"Pharmazentrum Frankfurt\/ZAFES, Klinikum der Goethe Universit\u00e4t, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Pfeilschifter","sequence":"additional","affiliation":[{"name":"Pharmazentrum Frankfurt\/ZAFES, Klinikum der Goethe Universit\u00e4t, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Hintermann","sequence":"additional","affiliation":[{"name":"Pharmazentrum Frankfurt\/ZAFES, Klinikum der Goethe Universit\u00e4t, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H-G","family":"Zerwes","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Christen","sequence":"additional","affiliation":[{"name":"Pharmazentrum Frankfurt\/ZAFES, Klinikum der Goethe Universit\u00e4t, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,6,7]]},"reference":[{"key":"2021122708473840100_b1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/08916930410001713124","article-title":"IP-10 and type 1 diabetes: a question of time and location","volume":"37","author":"Christen","year":"2004","journal-title":"Autoimmunity"},{"key":"2021122708473840100_b2","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.4049\/jimmunol.171.12.6838","article-title":"Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease","volume":"171","author":"Christen","year":"2003","journal-title":"J Immunol"},{"key":"2021122708473840100_b3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0092-8674(91)90165-U","article-title":"Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response","volume":"65","author":"Oldstone","year":"1991","journal-title":"Cell"},{"key":"2021122708473840100_b4","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/nm1202-792","article-title":"Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis","volume":"8","author":"Frigerio","year":"2002","journal-title":"Nat Med"},{"key":"2021122708473840100_b5","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.4049\/jimmunol.175.6.3516","article-title":"Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development","volume":"175","author":"Rhode","year":"2005","journal-title":"J Immunol"},{"key":"2021122708473840100_b6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1084\/jem.193.8.975","article-title":"Donor-derived IP-10 initiates development of acute allograft rejection","volume":"193","author":"Hancock","year":"2001","journal-title":"J Exp Med"},{"key":"2021122708473840100_b7","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1084\/jem.192.10.1515","article-title":"Requirement of the chemokine receptor CXCR3 for acute allograft rejection","volume":"192","author":"Hancock","year":"2000","journal-title":"J Exp Med"},{"key":"2021122708473840100_b8","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/1521-4141(200108)31:8<2521::AID-IMMU2521>3.0.CO;2-Q","article-title":"Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection","volume":"31","author":"Meyer","year":"2001","journal-title":"Eur J Immunol"},{"key":"2021122708473840100_b9","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0002-9440(10)64407-0","article-title":"The role of MIG\/CXCL9 in cardiac allograft vasculopathy","volume":"161","author":"Yun","year":"2002","journal-title":"Am J Pathol"},{"key":"2021122708473840100_b10","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/00007890-200112270-00016","article-title":"Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants","volume":"72","author":"Goddard","year":"2001","journal-title":"Transplantation"},{"key":"2021122708473840100_b11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/ajkd.2001.22076","article-title":"Expression of chemokines and chemokine receptors during human renal transplant rejection","volume":"37","author":"Segerer","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"2021122708473840100_b12","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/j.1600-6143.2008.02250.x","article-title":"Unaltered graft survival and intragraft lymphocytes infiltration in the cardiac allograft of Cxcr3\u2013\/\u2013 mouse recipients","volume":"8","author":"Kwun","year":"2008","journal-title":"Am J Transplant"},{"key":"2021122708473840100_b13","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/j.1600-6143.2008.02309.x","article-title":"The chemokine receptor Cxcr3 is not essential for acute cardiac allograft rejection in mice and rats","volume":"8","author":"Zerwes","year":"2008","journal-title":"Am J Transplant"},{"key":"2021122708473840100_b14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nri2747","article-title":"Strategies and challenges for the next generation of therapeutic antibodies","volume":"10","author":"Beck","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"2021122708473840100_b15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri2761","article-title":"Therapeutic antibodies for autoimmunity and inflammation","volume":"10","author":"Chan","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"2021122708473840100_b16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1517\/13543780903535867","article-title":"Anti-chemokine small molecule drugs: a promising future?","volume":"19","author":"Proudfoot","year":"2010","journal-title":"Exp Opin Investig Drugs"},{"key":"2021122708473840100_b17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd1134","article-title":"The bicyclam AMD3100 story","volume":"2","author":"De Clercq","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"2021122708473840100_b18","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0149-2918(08)80048-3","article-title":"Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection","volume":"30","author":"Lieberman-Blum","year":"2008","journal-title":"Clin Ther"},{"key":"2021122708473840100_b19","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1016\/j.bmcl.2009.09.002","article-title":"Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead","volume":"19","author":"Thoma","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"2021122708473840100_b20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/1074-7613(94)90101-5","article-title":"How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model","volume":"1","author":"von Herrath","year":"1994","journal-title":"Immunity"},{"key":"2021122708473840100_b21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1600-0625.2008.00793.x","article-title":"Computer-aided analysis of cell interactions under dynamic flow conditions","volume":"18","author":"Giegold","year":"2009","journal-title":"Exp Dermatol"},{"key":"2021122708473840100_b22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1074-7613(00)80200-9","article-title":"IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection","volume":"12","author":"Khan","year":"2000","journal-title":"Immunity"},{"key":"2021122708473840100_b23","doi-asserted-by":"crossref","first-page":"7023","DOI":"10.4049\/jimmunol.166.12.7023","article-title":"A dual role for TNF-alpha in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis","volume":"166","author":"Christen","year":"2001","journal-title":"J Immunol"},{"key":"2021122708473840100_b24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1172\/JCI17005","article-title":"Cure of prediabetic mice by viral infections involves lymphocyte recruitment along an IP-10 gradient","volume":"113","author":"Christen","year":"2004","journal-title":"J Clin Invest"},{"key":"2021122708473840100_b25","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jaut.2010.09.003","article-title":"CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation","volume":"35","author":"Hintermann","year":"2010","journal-title":"J Autoimmun"},{"key":"2021122708473840100_b26","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.4049\/jimmunol.179.12.8463","article-title":"Blockade of chemokine receptor CXCR3 inhibits T cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis","volume":"179","author":"Mohan","year":"2007","journal-title":"J Immunol"},{"key":"2021122708473840100_b27","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.4049\/jimmunol.0802626","article-title":"CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis","volume":"183","author":"Steinmetz","year":"2009","journal-title":"J Immunol"},{"key":"2021122708473840100_b28","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1750-3639.2008.00154.x","article-title":"Antagonism of the chemokine receptors CXCR3 and CXCR4 reduces the pathology of experimental autoimmune encephalomyelitis","volume":"18","author":"Kohler","year":"2008","journal-title":"Brain Pathol"},{"key":"2021122708473840100_b29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1084\/jem.187.6.875","article-title":"Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes","volume":"187","author":"Sallusto","year":"1998","journal-title":"J Exp Med"},{"key":"2021122708473840100_b30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/187153007780059405","article-title":"Chemokines as drug targets in type 1 diabetes","volume":"7","author":"Christen","year":"2007","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"2021122708473840100_b31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0092-8674(91)90164-T","article-title":"Ablation of tolerance and induction of diabetes by virus infection in viral antigen transgenic mice","volume":"65","author":"Ohashi","year":"1991","journal-title":"Cell"},{"key":"2021122708473840100_b32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0070-2153(05)68006-4","article-title":"Chemokine receptor CXCR3: an unexpected enigma","volume":"68","author":"Liu","year":"2005","journal-title":"Curr Top Dev Biol"},{"key":"2021122708473840100_b33","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.4049\/jimmunol.176.8.4716","article-title":"IFN-gamma acts on T cells to induce NK cell mobilization and accumulation in target organs","volume":"176","author":"Wald","year":"2006","journal-title":"J Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2011.04426.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/165\/3\/318\/41909060\/j.1365-2249.2011.04426.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/165\/3\/318\/41909060\/j.1365-2249.2011.04426.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T10:31:40Z","timestamp":1712485900000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/165\/3\/318\/6422874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,7]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,6,7]]},"published-print":{"date-parts":[[2011,8,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2011.04426.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,9]]},"published":{"date-parts":[[2011,6,7]]}}}